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Objective: This article will address the effect of exacer-
bation status, disease severity (deﬁned by medication
required), and other variables on resource use and costs
for asthma in Switzerland in 1996 to 1997.
Methods: A retrospective chart-based study was per-
formed. A sample of 422 adults was analyzed. Target
variables were stratiﬁed by disease severity and exacer-
bation status. Bivariate associations were assessed. Mul-
tiple linear regression was performed on the logarithm of
direct medical costs.
Results: The probability of exacerbations was positively
associated with disease severity. Resource use and costs
were associated with both of these variables. Multiple
linear regression identiﬁed age, presence of asthma-
related comorbidities, degree of severity, exacerbation
status, quick reliever versus controller therapy, and diag-
nosis or treatment by a pulmonologist as independent
inﬂuences on direct costs. An interaction between sever-
ity and exacerbation status was also noted. Regression
identiﬁed direct costs in the highest severity group to be
2.5 times higher than those in the lowest group, if there
were no exacerbations. If exacerbations were present,
costs were 5.7 times higher.
Conclusions: Because of its high prevalence, asthma has
a high impact on public health. This impact depends on
disease severity and, according to these ﬁndings, may also
depend on the extent to which exacerbations are avoided
or at least controlled.
Keywords: asthma, disease severity, resource use, cost of
illness, economics, Switzerland.
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ABSTRACT
Introduction
Asthma seriously affects both children and adults,
and the prevalence of asthma has increased consid-
erably during the past three decades [1,2]. The
disease affects between 4% and 8% of the popula-
tion in industrialized countries [3–6]. In Switzer-
land, Leuenberger [7] has reliably estimated
prevalence at 6.7% in adults.
Diseases with such high prevalence require
detailed knowledge not only of their clinical and
medical aspects, but also of their economic impli-
cations. Information on the costs and cost structure
of asthma is essential for sound health policy deci-
sions in the ﬁeld of respiratory diseases. Studies on
the costs of asthma have therefore been performed
in the United States as well as, more rarely, in Euro-
pean and other countries, as seen in an overview
given in a recent article by Weiss and Sullivan [8].
Data from Switzerland on this topic, however,
are sparse. In 1996 to 1997, Szucs and colleagues
[9,10] published an analysis of the resource use 
and cost structure of asthma in Switzerland. They
demonstrated that asthma has a large economic
impact, with total costs of Swiss Francs (CHF) 1250
million per year and a structure of direct medical
costs dominated by medication costs in children and
by hospitalization costs in adults. No further Swiss
data have been published.
The current analysis was based on the data set
collected by Szucs and colleagues [10]. The goal was
to identify independent determinants of asthma-
related resource use and of direct medical asthma
costs in adult Swiss patients. Particular importance
was given to the impact of asthma severity and
exacerbation status on direct medical costs.
Materials and Methods
Patient Sample and Study Design
The original data set by Szucs and colleagues [10]
comprised 589 patients who were treated by 120
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primary care physicians. There were 472 adults and
117 children aged 14 years or younger. The latter
were excluded from this analysis because their clin-
ical and economic characteristics differ consider-
ably from those of the adult population.
Szucs et al. [10] collected data by retrospective
chart review. There was a 1-year reference period 
in 1996 to 1997. Assessment of asthma-speciﬁc
resource use comprised physician visits, hospital
care, and medication. The decision as to whether 
a particular resource use was asthma-speciﬁc or 
not was left to the physician’s judgment. The chart
extractors were advanced medical students. Stu-
dents performed extractions in the participating
physicians’ ofﬁces and in close contact with the
physicians. Any uncertainties had to be clariﬁed
with and decided by the physicians. Data on 
community nursing were not collected, because 
this kind of service provision does not play a 
major role in Swiss asthma management. The 
possibility cannot be ruled out that some patients
received unrecorded asthma-speciﬁc services from
other physicians. These facts may have led to a
modest underestimation of absolute direct medical
costs.
Loss of work because of personal illness or
caring for relatives was recorded as a basis for cal-
culating indirect costs that are not considered in this
analysis. Additional information was collected on
disease duration, demographics, and physiological
variables, comprising height, weight, body mass
index (BMI), 1-s forced expiratory volume (FEV1),
and forced vital capacity (FVC). Asthma-related
comorbidities were assessed by explicitly asking for
the presence of chronic bronchitis, emphysema, cor
pulmonale, reﬂux disease, and others.
Reliable health-care related cost estimates are
difﬁcult to obtain in Switzerland, because there 
are no large administrative databases allowing for
access to claims data. Most health insurance com-
panies are reluctant to provide case-speciﬁc cost
information. In this situation, Szucs and colleagues
[10] proceeded as follows to calculate direct
medical costs from a health system perspective:
Asthma-speciﬁc resource units were derived from
the physician’s medical charts as stated above. In the
case of medication, prescriptions were used as a
proxy of use. Unit costs were estimated as follows:
First, the average charge per inpatient day on the
general ward of a public acute care hospital was cal-
culated from a tariff list covering all Swiss hospitals
[11]. Cantonal subsidies were added to this average
charge, to obtain a proxy of hospitalization costs.
Second, costs of physician visits were calculated
individually, based on the services performed. Mean
charges per service were calculated from seven
regional tariff lists (representing German and
French speaking Switzerland) and used as proxy
measures for costs. Third, medication unit costs
were assumed to be represented by the Swiss public
prescription prices as stated in the 1997 Swiss Drug
Compendium [12]. All costs indicated in this article
are given in 1997 CHF. In mid-1997, at the end of
the reference period of the data collection, CHF 
1 = US$ 0.68.
Assessment of disease severity was not an explicit
goal of the original study. Therefore, degree-of-
severity classiﬁcation was based on the 1995 Global
Initiative for Asthma recommendations on medica-
tion use, which were in effect at the time of data
collection [13]. This kind of procedure has been rec-
ommended if clinical information is insufﬁcient
[14]. Physicians’ prescriptions and dose instructions
were used as a proxy of real medication use.
Patients who, according to this information, regu-
larly used short-acting b2-agonists only were 
classiﬁed as “mild intermittent.” Patients regularly
using inhaled corticosteroids, alone or in combina-
tion, were classiﬁed as “mild persistent.” Patients
regularly using long-acting b2-agonists or systemic
corticosteroids, alone or in combination, were 
classiﬁed as “moderate persistent” or “severe per-
sistent,” respectively. Complementary information
was available on treatment type, that is, quick
reliever versus controller therapy as deﬁned by the
treating physician, without any pregiven reference
to guidelines, and on the presence or absence of
asthma attacks/exacerbations, as deﬁned by the
treating physician during the reference period. The
remaining sample comprised 422 patients; 50
patients were excluded due to lack of data for one
or more of these variables. Exacerbations were not
necessarily associated with a resource use episode.
They could be self-reported to the treating physi-
cian at a later point in time.
Statistical Methods
Demographic and disease characteristics are pre-
sented in comparison with the complete adult study
sample. Exacerbation frequencies were stratiﬁed by
degree of severity. A chi-squared trend test was used
to evaluate the differences observed. Main resource
use and cost variables were stratiﬁed by degree of
severity and exacerbation status.
Bivariate associations were assessed among
direct medical costs, degree of severity, exacerbation
status, and other possible inﬂuences. Costs were
heavily right-skewed, but logarithmic transforma-
77Costs of Asthma in Swiss Adults
tion achieved an approximately normal distribu-
tion. Nonparametric tests of the untransformed 
and Student’s t tests of the transformed cost vari-
able were used. In general, chi-squared tests were
used to compare two categorical variables. If one
variable was continuous, Mann–Whitney U tests/
Kruskal–Wallis tests, or Student’s t tests/ANOVA
were used as appropriate [15]. If both variables
were continuous, Spearman’s or Pearson’s correla-
tion coefﬁcients were calculated. Least-squares
regression was used to evaluate interaction between
degree of severity and exacerbation status in their
effect on the number of physician visits, specialist
referrals, and hospitalizations.
Finally, multiple least squares regression was per-
formed on the logarithm of direct medical costs.
Independent variables qualiﬁed as possible inﬂuence
factors if an association with direct medical costs
could reasonably be assumed (P = .2 in bivariate
analysis). Resource use variables that were direct
contributors to costs (e.g., emergency room visits,
days spent in hospital) were excluded. Nevertheless
there may be a problem of circularity, particularly
because disease severity, in the absence of other
options, was deﬁned by medication use and thus
directly linked to (medication) costs. Similar corre-
lations may affect the treatment type variable and
other parameters, albeit to a much lesser extent. To
assess the scope of this problem, an additional
regression was performed on the logarithm of direct
medical costs excluding medication costs, and the
proportion of the variance of medication costs
explained by the degree-of-severity and treatment
type variables was calculated. In all cases P = .05
was used as the level of statistical signiﬁcance, and
P values were two-tailed.
All calculations were performed using STATA
(1999, Version 6.0) and SPSS (1999, version 10.0).
Results
Patient Characteristics
The demographic and disease-speciﬁc characteris-
tics of the patient sample studied are shown in 
Table 1. In comparison with the complete adult
study population, there were no unexpected differ-
ences. The percentage of patients with exacerba-
tions was slightly higher, but the mean number of
exacerbations was lower in the analyzed sample.
Fewer French-speaking patients were included 
due to a higher number of missing degree-of-
severity or exacerbation status data. Over 50% of
the FEV1, FVC, and absence-from-work data were
missing.
Degree of Severity and Exacerbation Status
The distributions of the medication-derived degree
of severity groups and the occurrence and number
of exacerbations are shown in Table 1. Spearman’s
correlation between FEV1 and medication-based
degree of severity was -0.22 (P = .002).
The proportion of patients who experienced at
least one exacerbation during the reference 
period was almost constant in the mild intermittent
(31.8%) to moderate persistent (31.1%) groups,
with a minimum in the patients classiﬁed as mild
persistent (28.2%). This percentage was distinctly
higher in the severe persistent group (54.1%),
leading to a highly signiﬁcant chi-squared trend test
(p < .0005).
Resource Use
The presence of exacerbations during the reference
period was signiﬁcantly associated with more physi-
cian visits (7.2 vs. 4.9, P < .005), specialist referrals
(0.33 vs. 0.17, P = .048), and hospitalizations (0.19
vs. 0.015, P < .005) per year. Similar associations
with degree of severity were observed; there were
7.9 versus 3.8 physician visits (P < .005), 0.3 versus
0.02 specialist referrals (P = .13), and 0.16 versus
0.02 hospitalizations (P = .05) per year in the
highest versus lowest severity groups. Stratiﬁcation
by both exacerbation status and severity is shown
in Table 2. Again, the number of resource units con-
sumed increased with severity, and higher levels
were reached in the presence of exacerbations.
These tendencies were evident in all subgroups,
albeit somewhat less unambiguously in the special-
ist referrals. Regression analysis demonstrated
interaction between degree of severity and exacer-
bation status in their effect on the number of physi-
cian visits (P = .03 for a set of three dummy
variables representing interaction) and hospitaliza-
tions (P = .04), but not the number of specialist
referrals (P = .53).
Costs
The presence of exacerbations during the reference
period was associated with higher direct medical
costs (CHF 3202 vs. CHF 1029, P = .0001), physi-
cian costs (CHF 269 vs. CHF 207, P < .00005),
medication costs (CHF 724 vs. CHF 901, P = .056),
and hospitalization costs (CHF 2031 vs. CHF 99,
P < .00005) per year. There also was a steady
increase with degree of severity. In the highest
versus lowest severity groups, direct medical costs
were CHF 3075 versus CHF 627, physician 
costs were CHF 284 versus CHF 109, medication
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costs were CHF 1122 versus CHF 336, and hospi-
tal costs were CHF 1669 versus CHF 182 (p < .005
in all cases). Stratiﬁcation by exacerbation status as
well as severity revealed further details (Table 3). In
the patients with no exacerbations, there was a clear
positive association of severity with direct medical
costs and medication costs, but less of an associa-
tion with physician costs and no association with
hospitalization costs. In absolute terms, hospital-
ization costs were minimal here. In the patients who
experienced exacerbations, a positive association
with severity was seen in all cost categories.
Absolute hospitalization costs were important here.
In the moderate and severe patients with hospital-
izations, mean hospitalization costs were CHF
10333 (SD 7018) and CHF 13875 (SD 11039),
respectively.
Consequently, the relative proportions of cost
categories differed greatly between those with and
without exacerbations: In the latter, physician costs
accounted for 20.1% of total direct medical costs,
medication costs accounted for 70.4%, and hospi-
talization costs for 9.6%. In those with exacerba-
tions, physician costs contributed 8.4% and
medication costs contributed 28.1%, but hospital-
ization costs contributed 63.4%. The absolute
levels of physician and medication costs in those
with exacerbations were only slightly higher than in
Table 1 Demographic and disease-speciﬁc characteristics of study population
Value (mean ± SD or %)
Adults: information on severity Complete adult study
and exacerbation status available (n = 422)* sample (n = 472)*
Age (years) 53.4 ± 20.6 52.5 ± 20.8
German/French speaking (%) 78.0/22.0 75.4/24.6
Height (cm) 167.0 ± 8.9 (n = 219) 167.3 ± 9.3 (n = 246)
Weight (kg) 72.0 ± 15.0 (n = 240) 72.0 ± 15.7 (n = 268)
BMI (m/kg2) 25.8 ± 5.4 (n = 204) 25.6 ± 5.3 (n = 231)
FEV1 (L/sec) 2.4 ± 1.0 (n = 193) 2.5 ± 1.1 (n = 216)
FVC (L) 3.3 ± 1.3 (n = 173) 3.3 ± 1.3 (n = 192)
Duration of asthma (years) 12.4 ± 12.8 (n = 268) 11.3 ± 12.5 (n = 301)
Employed (%) 44.2 (n = 410) 45.6 (n = 458)
Absences from work (% of employed) 25.8 (n = 168) 23.9 (n = 188 of 209)
Type of treatment (n = 461)
Quick reliever therapy (%)† 23.7 24.9
Controller therapy (%)† 76.3 75.1
Degree of severity (GINA) (n = 432)
Mild intermittent (%) 10.4 10.7
Mild persistent (%) 26.0 26.2
Moderate persistent (%) 32.0 31.9
Severe persistent (%) 31.5 31.3
Presence of exacerbation(s) during 
observation period (%) (n = 422) 37.7 36.4
Number of exacerbations‡ (n = 159) 1.6 ± 1.3 1.8 ± 2.5
*Differing sample sizes owing to missing values are indicated separately.
†Quick reliever therapy, treatment only when symptoms occur; controller therapy, prophylactic treatment.
‡Base, patients with exacerbations.
Abbreviation: GINA, Global Initiative for Asthma.
Table 2 Resource use by degree of severity and exacerbation status in units per patient-year
Group N Physician visits* Specialist referrals* No. of hospitalizations*
Total sample 422 5.8 ± 5.0 0.23 ± 0.80 0.083 ± 0.34
Exacerbations absent 263 4.9 ± 4.5 0.17 ± 0.68 0.015 ± 0.12
By degree of severity
Mild intermittent 30 3.7 ± 4.5 0.033 ± 0.18 0.033 ± 0.18
Mild persistent 79 4.1 ± 4.7 0.18 ± 0.53 0.013 ± 0.11
Moderate persistent 39 5.2 ± 4.0 0.16 ± 0.52 0.011 ± 0.10
Severe persistent 61 6.3 ± 4.7 0.25 ± 1.1 0.016 ± 0.13
Exacerbations present 159 7.2 ± 5.4 0.33 ± 0.96 0.19 ± 0.51
By degree of severity
Mild intermittent 14 4 ± 2.7 0 ± 0 0 ± 0
Mild persistent 31 4 ± 3.4 0.29 ± 0.78 0.097 ± 0.30
Moderate persistent 42 7.1 ± 5.3 0.45 ± 1.3 0.19 ± 0.40
Severe persistent 72 9.3 ± 5.7 0.35 ± 0.86 0.27 ± 0.65
*Mean ± SD.
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those without exacerbations. To a very large extent,
hospitalization costs accounted for the differences
observed.
Spearman’s correlation coefﬁcients of annual
direct medical costs with the number of physician
visits (.69), the number of specialist referrals (.14),
and the number of hospitalizations (.44) were sig-
niﬁcant at the 5% level (P < .005 in all three cases).
Spearman’s correlation coefﬁcients, however, with
possible nonresource use inﬂuence factors were
weak, except in the case of age (.25, P < .005),
FEV1 (–.19, P = .008), and disease duration (.13, 
P = .033). Pearson’s coefﬁcients of the same vari-
ables with the logarithm of direct costs were almost
identical. There appeared to be no relevant correla-
tions between costs and BMI or FVC.
Mann–Whitney U or Kruskal–Wallis tests
revealed signiﬁcantly higher costs for the following
inﬂuences: controller therapy compared to quick
reliever therapy (P < .005); involvement of a pul-
monologist in diagnosis or regular treatment (P <
.005); nonemployment at the beginning of the ref-
erence period in patients aged 65 or younger (P =
.005); and presence of asthma-related comorbidities
(P = .029). The use of Student’s t tests or ANOVA
with the logarithm of direct costs led to the same
results. Absences from work in the employed,
German language region, and rural versus urban
dwelling were associated with higher costs and had
nonsigniﬁcant P values below .2, whereby these
factors qualiﬁed as candidate predictors in multi-
variate analysis. Evaluation by insurance coverage
did not reveal any existing associations.
There were no unexpected associations between
possible inﬂuence factors on direct costs. Degree of
severity and treatment type correlated signiﬁcantly
(P < .00005), but Spearman’s correlation coefﬁcient
was only .33.
Multivariate Analysis of Direct Medical Costs
Multiple regression analysis on direct medical costs
was based on the following possible inﬂuence
factors derived from bivariate analysis: degree of
severity, presence of exacerbations, quick reliever
versus controller therapy, involvement of a pulmo-
nologist (in diagnosis or regular treatment), age,
duration of disease, FEV1, presence of asthma-
related comorbidities, employment status, absences
from work, language region, and urban or rural
dwelling. Other potential inﬂuences such as height,
weight, BMI, and FVC were also explored.
Resource use variables (e.g., number of physician
visits, number of hospital days) were not taken into
account, because they were direct contributors to
costs.
Models using the logarithm of direct medical
costs identiﬁed degree of severity, exacerbation
status, quick reliever versus controller therapy, age
and age squared, presence of asthma-related comor-
bidities, and involvement of a pulmonologist (in
diagnosis or regular treatment) as relevant and sig-
niﬁcant inﬂuence factors, allowing for an adjusted
R2 value of .34. Inﬂuences of language region and
urban versus rural dwelling were not conﬁrmed.
A four-level ordinal variable, represented by
three dummy variables, was introduced in the
model to allow for interaction between medication-
based degree of severity and exacerbation status.
Thus, the effect of exacerbations could be described
separately for each degree of severity. This resulted
in a partial F test with P value of .0008 for the set
of dummy variables and increased the adjusted R2
value to .36, showing a greater effect of exacerba-
tions on costs in the more severe asthma patients.
Terms representing employment status in the
patients aged 65 or younger, and absences from
Table 3 Costs by degree of severity and exacerbation status in CHF per patient-year
Group n Direct medical costs* Physician costs* Medication costs* Hospitalization costs*
Total sample 422 1848 ± 4134 230 ± 257 791 ± 746 827 ± 3887
Exacerbations absent 263 1029 ± 1274 207 ± 266 724 ± 654 99 ± 1010
By degree of severity
Mild intermittent 30 708 ± 1509 99 ± 101 342 ± 481 267 ± 1461
Mild persistent 79 804 ± 676 225 ± 362 541 ± 380 38 ± 338
Moderate persistent 93 1187 ± 1617 211 ± 217 826 ± 516 151 ± 1452
Severe persistent 61 1238 ± 1089 229 ± 230 992 ± 978 16 ± 128
Exacerbations present 159 3202 ± 6315 269 ± 237 901 ± 868 2031 ± 6019
By degree of severity
Mild intermittent 14 452 ± 476 130 ± 75 322 ± 433 0 ± 0
Mild persistent 31 1275 ± 3249 153 ± 134 380 ± 329 742 ± 3151
Moderate persistent 42 3089 ± 4947 297 ± 224 912 ± 789 1881 ± 4964
Severe persistent 72 4631 ± 8058 331 ± 272 1231 ± 969 3069 ± 7717
*Mean ± SD.
Abbreviation: CHF, Swiss Francs.
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work in the employed, were not included in the ﬁnal
analysis albeit signiﬁcant or near signiﬁcant,
because they altered the model only slightly
(adjusted R2 = .38).
Age and age squared were centered to avoid a
colinearity problem with these variables. After 
this procedure, variance inﬂation factors showed a
mean of 3.91. The highest value was seen in the
exacerbation status variable (VIF 10.60), with the
dummy variables representing interaction between
degree of severity and exacerbation status showing
VIFs of 8.28, 5.26, and 4.40. Other criteria were
clearly noncritical: there were no standardized
regression coefﬁcients larger than 1. After inclusion
of the interaction terms, the parameter estimates
and standard errors for the other variables changed
very little, except of course for those terms which
were bound to change because their meaning is dif-
ferent in the model with the interaction terms.
Details of the main model (n = 420) are shown
in Table 4. In larger models including other poten-
tial confounders, the degree of severity and exacer-
bation variables, and the respective interaction
terms, had very similar coefﬁcients. Relevant coef-
ﬁcient changes only occurred when FEV1 and body
height or BMI were included. These models,
though, had to rely on less than 100 observations.
Residual analysis (based on scatter plots of resid-
uals vs. predicted values and age, box plots of resid-
uals grouped by noncontinuous inﬂuence factors,
and normality plots of residuals) gave satisfactory
results. Exclusion of inﬂuential points identiﬁed by
Cook’s distance and the covariance ratio (resulting
n = 393) did not affect signiﬁcance or greatly alter
coefﬁcients, but increased the R2 value to .43. Alter-
native versions of the model, for example, using the
frequency of exacerbations rather than their pres-
ence or absence, gave very similar results.
Costs increased with age, but the effect was mild,
nonlinear, and less pronounced in older age groups.
Assuming constant other parameters, the presence
of asthma-related comorbidities was associated
with a 50% increase in direct medical asthma costs,
controller therapy versus quick reliever therapy
with an 80% increase, and involvement of a pul-
monologist in diagnosis or treatment with a 30%
increase. Greater degrees of severity and the pres-
ence of exacerbations during the reference period
were also associated with higher costs (Table 5).
Because the effect of these variables is greater than
multiplicative, patients with a greater degree of
asthma severity who experienced exacerbations
were particularly expensive. Patients classed as
severe persistent who experienced exacerbations
cost more than ﬁve times as much as mild inter-
mittent patients who did not.
Regression analysis on the logarithm of direct
medical costs excluding medication costs resulted in
Table 4 Multiple linear regression on the logarithm of direct medical costs (n = 420)
F(12, 407) = 20.63; P > F = 0.0000; R2 = .3782; adjusted R2 = .3599
Covariates Coefﬁcient SE t P > |t| 95% CI
Degree of severity
Mild persistent 0.8218005* 0.1960516 4.19 <.0005 0.4364003 to 1.207201
Moderate persistent 1.012774* 0.1929955 5.25 <.0005 0.6333813 to 1.392166
Severe persistent 0.8962967* 0.2053643 4.36 <.0005 0.4925895 to 1.300004
Exacerbations present† 0.308257‡ 0.2965676 1.04 .299 -0.2747384 to 0.8912525
Interaction variable, ordinal§
Level 1 -0.4850357|| 0.3542102 -1.37 .172¶ -1.181346 to 0.2112742
Level 2 0.2323904|| 0.341103 0.68 .496¶ -0.4381532 to 0.9029339
Level 3 0.5271099|| 0.3369162 1.56 .118¶ -0.1352033 to 1.189423
Age (centered) 0.0054129 0.0023979 2.26 .025 0.000699 to 0.0101268
Age squared (centered) -0.0002552 0.0001084 -2.36 .019 -0.0004683 to -0.0000422
Asthma-related comorbiditiy present†¶ 0.37321 0.1267628 2.94 .003 0.1240184 to 0.6224016
Involvement of pulmonologist† 0.2758121 0.09196 3.00 .003 0.0950363 to 0.456588
Controller therapy† 0.6000914** 0.1160486 5.17 <.0005 0.3719619 to 0.8282209
Intercept 5.14959 0.1849907 27.84 <.0005 4.785934 to 5.513247
*Compared to mild intermittent.
†Dichotomous variables, values coded “0” or “1.” Presence of exacerbations, presence of comorbidities, involvement of a pulmonologist in diagnosis or treatment,
and controller therapy are coded “1.”
‡This coefﬁcient indicates the effect of exacerbations being present in a patient with the lowest degree of severity.The effect of exacerbations at higher degrees
of severity is the sum of this coefﬁcient and that for the relevant interaction term.
§Levels 1 to 3 represent a four-level ordinal interaction variable. The reference is level 0, which summarizes all situations without exacerbations or a degree of
severity higher than “mild intermittent” being present. Using more levels instead did not result in any further improvement of the model. The effect of exacer-
bations being present in mild intermittent patients is modeled by the “exacerbations present” term of the model. Levels 1 through 3 represent the additional effect
of exacerbations being present in patients with mild persistent, moderate persistent, or severe persistent asthma.
||Compared to level 0.
¶Partial F test for this set of variables: P = .0008.
**Compared to quick reliever therapy.
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a model comprising the same inﬂuence factors as
described above, except for age and the interaction
term between degree of severity and exacerbation
status (n = 420, R2 = .22). These variables them-
selves remained highly signiﬁcant. Degree of sever-
ity and treatment type accounted for 19% of the
variance seen in the medication costs.
Discussion
This analysis is concerned with the determinants of
the direct medical costs of adult asthma, which are
most relevant from a third-party payer perspective.
An inclusion of indirect costs, whose analysis may
require a different set of predictors, was not under-
taken.
Stratiﬁcation by exacerbation status and degree
of severity reveals these variables to be positively
associated with all subcategories of direct medical
costs. However, there is no association between
severity and hospitalization costs in the patients
without exacerbations. In those with exacerbations,
such an association is clearly present. In absolute
terms, the cost difference observed between those
with and without exacerbations mainly stems from
dramatically increased hospitalization costs, while
the levels of physician and medication costs are only
slightly higher.
The multiple regression model presented identi-
ﬁes a set of factors, which while easy to measure,
explain a considerable percentage of the variance
seen in the direct medical costs of asthma. Age,
comorbidity status, and several factors linked to the
concept of disease severity (primarily degree of
severity deﬁned by medication and exacerbation
status) inﬂuence the direct medical costs of asthma.
Treatment type (quick reliever vs. controller
therapy, as judged by the treating physician) reﬂects
treatment habits, but also comprises aspects of
disease severity. The same is probably true for the
involvement of a pulmonologist, which can be
assumed to be more frequent in cases that are more
difﬁcult to treat. If so, the higher cost associated
with such an involvement can be expected to be
partly due to patient or disease characteristics not
covered by our degree-of-severity variable. Differ-
ent treatment patterns in similar patients would be
an additional or alternative explanation. However,
there is some evidence that these patterns, albeit
more costly at the outpatient level, are cost saving
overall by reducing complication costs [9].
It may seem improper to include several explana-
tory variables linked to the concept of disease sever-
ity that directly impact on cost, which is the
outcome variable. In particular, the use of medica-
tion as a proxy measure of severity may over-
estimate the impact of this factor on costs and
introduces circularity, which may exaggerate statis-
tical signiﬁcance. It also assumes that empirical
treatment follows guidelines, at least to a certain
extent. In contrast, the results obtained demonstrate
that the economic impact of the degree-of-severity
and treatment type variables was not restricted 
to medication costs (representing 43% of direct
medical costs) and that the latter were not to a very
large extent explained by these variables. In clinical
terms, a higher degree of severity, deﬁned by med-
ication use, is probably associated with higher base-
line medication costs (drug costs per usual daily
dose), but also with considerably greater amounts
of medication needed and, as conﬁrmed by resource
use analysis, other health-care resources consumed.
Restriction of regression analysis to the nonmed-
ication costs would exclude the ﬁrst of these two
aspects and therefore lead to an incomplete picture.
The ﬁnding that greater degrees of asthma sever-
ity lead to higher medical costs conﬁrms the results
of other studies [8,16–20]. The ﬁndings of our 
multivariate analysis are in accordance with data
obtained by Hoskins and colleagues [21] on the
inﬂuence of disease severity on the frequency of
asthma exacerbations and the inﬂuence of exacer-
bations on costs. However, detailed comparisons
are hindered by the different health systems and
methodologies used.
The modest impact of age on direct medical costs
in this analysis does not contradict other studies
[19,22]. Plaza et al. [22] reported the costs of
asthma patients aged 65 or older to be twice as high
as those of adults under 65, but the investigators
did not correct for disease severity or apply multi-
variate methods. The current analysis could not
demonstrate a signiﬁcant effect of insurance status.
Such an effect was described in other studies, but
insurance systems may induce greater cost differ-
Table 5 Effect of degree of severity and exacerbation status
on direct medical costs according to the estimated regres-
sion model
Multiplication factor (95% CI)*
Exacerbations Exacerbations
Degree of severity absent present
Mild intermittent 1 (reference) 1.4 (0.8–2.4)
Mild persistent 2.3 (1.5–3.3) 1.9 (1.2–3.0)
Moderate persistent 2.8 (1.9–4.0) 4.7 (3.1–7.3)
Severe persistent 2.5 (1.6–3.7) 5.7 (3.8–8.4)
*Calculations performed using STATA’s lincom command.
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ences in the United States and in Canada than in
Switzerland [19,20]. In the United States, health
plans differ greatly in terms of coverage, and situa-
tions of underinsurance have been reported [23,24].
In Canada, drug plan participation is an issue [19].
In Switzerland, participation in the statutory health
insurance, which is obligatory, guarantees a high
level of medical care to everybody.
Possible effects of BMI or FEV1 were difﬁcult to
assess because of missing values. Inclusion of these
variables led to models based on less than 100
observations. Relevant coefﬁcient changes of the
medication-based degree of severity and exacerba-
tion variables occurred, which supports the idea
that these variables and FEV1 contain competing
information on disease severity.
The current analysis was based on a data collec-
tion primarily targeted at resource use and costs,
not at identifying inﬂuence factors on costs. For this
reason it was not possible to take into account some
potentially important variables such as patient 
compliance, inhaler technique, or smoking status
[16,19,21,25]. Future studies addressing associa-
tions between costs and medical correlates of
asthma should assess these. Severity classiﬁcation
should be based on clinical parameters. A clear def-
inition of exacerbations would allow a distinction
between different kinds of events with different 
economic impacts, thus leading to more precise
results.
Despite the limitations discussed, the ﬁndings of
this multivariate analysis show that severity and the
presence of exacerbations have considerable and
interacting effects on direct medical costs of asthma.
Because of its high prevalence, asthma has a high
impact on public health. This impact depends on
disease severity and may also depend on the extent
to which exacerbations are avoided or at least con-
trolled. A prospective study would be needed to
ﬁnally clarify this issue. If the ﬁndings presented
here are conﬁrmed, further efforts at preventing
exacerbations may well be repaid in reduced treat-
ment costs, as well as reduced patient suffering.
This study was supported by an unrestricted educational
grant from Novartis Pharma AG, Basel, Switzerland.
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